ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

TUL108

A development code.

Its studies are mostly in Urinary Tract Infections, led by The United Laboratories International.

Furthest: phase 1, since Jul 14, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
The United Laboratories International11 open or runningphase 1since Jul 14, 2026Jul 14, 2026Dec 30, 2026phase 1 · NCT07719257

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2026First study: phase 1 study in Complicated Urinary Tract Infections(cUTI)First studyNCT07719257 · 72 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Complicated Urinary Tract Infections(cUTI)NCT07719257

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07719257Complicated Urinary Tract Infections(cUTI) · China1Not yet recruitingDec 30, 202672

How it is read

Names in the registry

  • “TUL108”, 2 entries

Codes read as this program: TUL108.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.